LPTN Profile
Lpath, Inc. was a biotechnology company that focused on the development of lipidomic-based therapeutics, which used bioactive lipids to treat various diseases. The company was founded in 2002 and was headquartered in San Diego, California.
Lpath's technology platform centered around its ImmuneY2™ drug discovery engine, which identified novel bioactive lipids for use in developing potential therapeutics. The company's lead product candidate was iSONEP™, which was being developed as a treatment for wet age-related macular degeneration (AMD).
However, in 2016, Lpath announced that it had entered into a merger agreement with Apollo Endosurgery, Inc., a company focused on developing medical devices for minimally invasive surgical procedures. As a result of the merger, Lpath became a wholly-owned subsidiary of Apollo Endosurgery, and its shares were no longer publicly traded.
|
